BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
Go back to BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)| (NASDAQ: BYSI) | Delayed: 2.27 +0.16 (7.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.11 | 52 Week High | $ | |||
| Open | $2.18 | 52 Week Low | $ | |||
| Day High | $2.38 | P/E | N/A | |||
| Day Low | $2.18 | EPS | $ | |||
| Volume | 92,401 | |||||
